{"clinical_study": {"@rank": "166", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 06, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04332835"}, "id_info": {"org_study_id": "ABN011-2", "nct_id": "NCT04332835"}, "brief_title": "Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study", "acronym": "CP-COVID-19", "official_title": "Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study", "sponsors": {"lead_sponsor": {"agency": "Universidad del Rosario", "agency_class": "Other"}, "collaborator": [{"agency": "Fundaci\u00f3n Universitaria de Ciencias de la Salud", "agency_class": "Other"}, {"agency": "CES University", "agency_class": "Other"}, {"agency": "Instituto Distrital de Ciencia Biotecnolog\u00eda e Innovacion en Salud", "agency_class": "Other"}]}, "source": "Universidad del Rosario", "oversight_info": {"has_dmc": "Yes", "is_fda_regulated_drug": "No", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "Convalescent plasma (CP) has been used in recent years as an empirical treatment strategy\n      when there is no vaccine or treatment available for infectious diseases. In the latest viral\n      epidemics, such as the Ebola outbreak in West Africa in 2014, the World Health Organization\n      issued a document outlining a protocol for the use of whole blood or plasma collected from\n      patients who have recovered from the Ebola virus disease by transfusion to empirically treat\n      local infectious outbreaks"}, "detailed_description": {"textblock": "The process is based on obtaining plasma from patients recovered from COVID-19 in Colombia,\n      and through a donation of plasma from the recovered, the subsequent transfusion of this to\n      patients infected with coronavirus disease (COVID-19). Our group has reviewed the scientific\n      evidence regarding the application of convalescent plasma for emergency viral outbreaks and\n      has recommended the following protocol"}, "overall_status": "Not yet recruiting", "start_date": {"@type": "Anticipated", "#text": "April 1, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "December 31, 2020"}, "primary_completion_date": {"@type": "Anticipated", "#text": "August 31, 2020"}, "phase": "Phase 2/Phase 3", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "primary_purpose": "Treatment", "masking": "None (Open Label)"}, "primary_outcome": [{"measure": "Change in Viral Load", "time_frame": "Days 0, 4, 7, 14 and 28", "description": "Copies of COVID-19 per ml"}, {"measure": "Change in Immunoglobulin M COVID-19 Titers", "time_frame": "Days 0, 4, 7, 14 and 28", "description": "Immunoglobulin M COVID-19 antibodies"}, {"measure": "Change in Immunoglobulin G COVID-19 Titers", "time_frame": "Days 0, 4, 7, 14 and 28", "description": "Immunoglobulin G COVID-19 antibodies"}], "secondary_outcome": [{"measure": "Intensive Care Unit Admission", "time_frame": "Days 7, 14 and 28", "description": "Proportion of patients with Intensive Care Unit Admission requirement (days 7, 14 and 28)"}, {"measure": "Length of Intensive Care Unit stay", "time_frame": "Days 7, 14 and 28", "description": "Days of Intensive Care Unit management (days 7, 14 and 28)"}, {"measure": "Length of hospital stay (days)", "time_frame": "Days 7, 14 and 28", "description": "Days of Hospitalization (days 7, 14 and 28)"}, {"measure": "Requirement of mechanical ventilation", "time_frame": "Days 7, 14 and 28", "description": "Proportion of patients with mechanical ventilation (days 7, 14 and 28)"}, {"measure": "Duration (days) of mechanical ventilation", "time_frame": "Days 7, 14 and 28", "description": "Days with mechanical ventilation (days 7, 14 and 28)"}, {"measure": "Clinical status assessed according to the World Health Organization guideline", "time_frame": "Days 7, 14 and 28", "description": "1. Hospital discharge; 2. Hospitalization, not requiring supplemental oxygen; 3. Hospitalization, requiring supplemental oxygen (but not Noninvasive Ventilation/ HFNC); 4. Intensive care unit/hospitalization, requiring Noninvasive Ventilation/ HFNC therapy; 5. Intensive care unit, requiring extracorporeal membrane oxygenation and/or invasive mechanical ventilation; 6. Death. (days 7, 14 and 28)"}, {"measure": "Mortality", "time_frame": "Days 7, 14 and 28", "description": "Proportion of death patients at days 7, 14 and 28"}], "number_of_arms": "2", "enrollment": {"@type": "Anticipated", "#text": "80"}, "condition": ["Coronavirus", "Coronavirus Infection"], "arm_group": [{"arm_group_label": "Intervention Group", "arm_group_type": "Experimental", "description": "Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol. Simultaneously, they will receive standard therapy Azithromycin (500 milligrams daily) and Hydroxychloroquine (400 milligrams each 12 hours) for 10 days."}, {"arm_group_label": "Control Group", "arm_group_type": "Active Comparator", "description": "Participants included in the control group will receive standard therapy Azithromycin (500 milligrams daily) and Hydroxychloroquine (400 milligrams each 12 hours) for 10 days."}], "intervention": [{"intervention_type": "Drug", "intervention_name": "Plasma", "description": "Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.", "arm_group_label": "Intervention Group", "other_name": "Convalescent Plasma COVID-19"}, {"intervention_type": "Drug", "intervention_name": "Hydroxychloroquine", "description": "400 milligrams each 12 hours for 10 days", "arm_group_label": ["Control Group", "Intervention Group"]}, {"intervention_type": "Drug", "intervention_name": "Azithromycin", "description": "500 milligrams daily for 10 days", "arm_group_label": ["Control Group", "Intervention Group"]}], "eligibility": {"criteria": {"textblock": "Inclusion Criteria:Fulfilling all the following criteria\n\n          1. Aged between 18 and 60 years, male or female.\n\n          2. Hospitalized participants with diagnosis of COVID 19 by Real Time - Polymerase Chain\n             Reaction.\n\n          3. Moderate cases according to the official guideline \"Pneumonia Diagnosis and Treatment\n             Scheme for Novel Coronavirus Infection (Trial Version 6)\".\n\n          4. Confusion, Urea, Respiratory rate, Blood pressure-65 (CURB-65) >= 2.\n\n          5. Sequential Organ Failure Assessment score (SOFA) < 6.\n\n          6. Ability to understand and the willingness to sign a written informed consent document.\n\n        Exclusion Criteria:\n\n          1. Female subjects who are pregnant or breastfeeding.\n\n          2. Patients with prior allergic reactions to transfusions.\n\n          3. Critical ill patients in intensive care units.\n\n          4. Patients with surgical procedures in the last 30 days.\n\n          5. Patients with active treatment for cancer (Radiotherapy or Chemotherapy).\n\n          6. HIV diagnosed patients with viral failure (detectable viral load> 1000 copies / ml\n             persistent, two consecutive viral load measurements within a 3 month interval, with\n             medication adherence between measurements after at least 6 months of starting a new\n             regimen antiretrovirals).\n\n          7. Patients who have suspicion or evidence of coinfections.\n\n          8. End-stage chronic kidney disease (Glomerular Filtration Rate <15 ml / min / 1.73 m2).\n\n          9. Child Pugh C stage liver cirrhosis.\n\n         10. High cardiac output diseases.\n\n         11. Autoimmune diseases or Immunoglobulin A nephropathy.\n\n         12. Patients have any condition that in the judgement of the Investigators would make the\n             subject inappropriate for entry into this study."}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "60 Years", "healthy_volunteers": "No"}, "overall_official": {"last_name": "Juan M Anaya Cabrera, MD, PhD", "role": "Study Director", "affiliation": "Universidad del Rosario"}, "overall_contact": {"last_name": "Juan M Anaya Cabrera, MD, PhD", "phone": "+57 321 233 9828", "email": "anayajm@gmail.com"}, "overall_contact_backup": {"last_name": "Manuel E Rojas Quintana, MD, MSc", "phone": "+57 315 459 9951", "email": "manuel_9316@hotmail.com"}, "location": {"facility": {"name": "Universidad del Rosario", "address": {"city": "Bogota", "state": "Cundinamarca", "zip": "11100", "country": "Colombia"}}, "contact": {"last_name": "Gustavo Quintero, MD, MSc", "phone": "+57 318 3606458", "email": "gustavo.quintero@urosario.edu.co"}, "investigator": [{"last_name": "Juan M Anaya Cabrera, MD, PhD", "role": "Principal Investigator"}, {"last_name": "Manuel E Rojas Quintana, MD, MSc", "role": "Sub-Investigator"}, {"last_name": "Sara Velez Gomez", "role": "Sub-Investigator"}, {"last_name": "Juan C Diaz Coronado, MD, MSc", "role": "Sub-Investigator"}, {"last_name": "Anha M Robledo Moreno", "role": "Sub-Investigator"}, {"last_name": "Juan E Gallo Bonilla, MSc, PhD", "role": "Sub-Investigator"}, {"last_name": "Ruben D Manrique Hern\u00e1ndez, MSc, PhD", "role": "Sub-Investigator"}, {"last_name": "Oscar M G\u00f3mez Guzm\u00e1n, MSc, PhD", "role": "Sub-Investigator"}, {"last_name": "Isaura P Torres G\u00f3mez, MSc, PhD", "role": "Sub-Investigator"}, {"last_name": "Paula A Pedroza Rodr\u00edguez", "role": "Sub-Investigator"}, {"last_name": "Bernardo Camacho Rodr\u00edguez, MD, MSc", "role": "Sub-Investigator"}, {"last_name": "Jeser S Grass Guaqueta, MSc", "role": "Sub-Investigator"}, {"last_name": "Gustavo A Salguero L\u00f3pez, MD, PhD", "role": "Sub-Investigator"}, {"last_name": "Luisa P Duarte Correales", "role": "Sub-Investigator"}, {"last_name": "Cristian A Ricaurte Perez, MSc", "role": "Sub-Investigator"}, {"last_name": "Adriana Rojas Villarraga, MD", "role": "Sub-Investigator"}, {"last_name": "Heily C Ram\u00edrez Santana, MSc, PhD", "role": "Sub-Investigator"}, {"last_name": "Diana M Monsalve Carmona, PhD", "role": "Sub-Investigator"}, {"last_name": "Yhojan A Rodr\u00edguez Velandia, MD", "role": "Sub-Investigator"}, {"last_name": "Yeny Y Acosta Ampudia, PhD", "role": "Sub-Investigator"}, {"last_name": "Carlos E Perez, MD", "role": "Sub-Investigator"}, {"last_name": "Ruben D Mantilla, MD", "role": "Sub-Investigator"}, {"last_name": "Paula Gaviria, MSc", "role": "Sub-Investigator"}]}, "location_countries": {"country": "Colombia"}, "link": {"url": "https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds", "description": "FDA recommendations for convalescent plasma clinical research"}, "reference": [{"citation": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.", "PMID": "31986264"}, {"citation": "Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020 Mar 5. doi: 10.1002/jmv.25748. [Epub ahead of print] Review.", "PMID": "32134116"}, {"citation": "Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, Ng OT, Marimuthu K, Ang LW, Mak TM, Lau SK, Anderson DE, Chan KS, Tan TY, Ng TY, Cui L, Said Z, Kurupatham L, Chen MI, Chan M, Vasoo S, Wang LF, Tan BH, Lin RTP, Lee VJM, Leo YS, Lye DC; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020 Mar 3. doi: 10.1001/jama.2020.3204. [Epub ahead of print]", "PMID": "32125362"}, {"citation": "Infectious, D. & Outbreaks, D. Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease ( COVID-19 ). OMS 1-5 (2020)"}], "verification_date": "April 2020", "study_first_submitted": "March 31, 2020", "study_first_submitted_qc": "April 1, 2020", "study_first_posted": {"@type": "Actual", "#text": "April 3, 2020"}, "last_update_submitted": "April 1, 2020", "last_update_submitted_qc": "April 1, 2020", "last_update_posted": {"@type": "Actual", "#text": "April 3, 2020"}, "responsible_party": {"responsible_party_type": "Principal Investigator", "investigator_affiliation": "Universidad del Rosario", "investigator_full_name": "Juan Manuel Anaya Cabrera", "investigator_title": "MD, PhD, Principal Investigator"}, "keyword": ["COVID-19", "Coronavirus Disease 2019"], "condition_browse": {"mesh_term": ["Coronavirus Infections", "Severe Acute Respiratory Syndrome"]}, "intervention_browse": {"mesh_term": "Hydroxychloroquine"}, "patient_data": {"sharing_ipd": "No"}}}